Publication

Equinor presents 2023 Integrated annual report

Retrieved on: 
Thursday, March 21, 2024
Annual report, Lindworm, Tax, Growth, Exchange, Snorre, Anders Opedal, GHG, Global warming potential, Gullfaks oil field, History, Acquisition, Security (finance), CCS, Nature, Carbon, Disclosure, Bank statement, Accident, Publication, CO2, Kilowatt-hour, Energy, ASA, Gina Krog, Use, Baugé, USD, NCS, Fatality, EQNR, Renewable energy

Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.

Key Points: 
  • Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.
  • The report for 2023 integrates the annual financial and sustainability reporting, reflecting the importance of sustainability for Equinor’s operational and financial performance, to our people, investors and other stakeholders.
  • The Equinor 2023 Annual Report on Form 20-F may be downloaded from Equinor's website at www.equinor.com.
  • See Use and reconciliation of non-GAAP financial measures in the integrated annual report for more details.

Gunderson Dettmer Selected as a 2024 BIG AI Excellence Winner for Generative AI

Retrieved on: 
Wednesday, March 20, 2024
Synthetic media, The Washington Post, Lead, AI, Bloomberg, Publication, International law, Artificial intelligence, Generative, Axios

The distinguished recipients include six prestigious technology leaders, 35 ground-breaking companies, and 79 leading AI platforms and products.

Key Points: 
  • The distinguished recipients include six prestigious technology leaders, 35 ground-breaking companies, and 79 leading AI platforms and products.
  • Chief among them were notable high-growth tech companies, several of which the firm represents in the AI vertical.
  • “Gunderson Dettmer has been pioneering the adoption of AI products for some time,” said Gunderson Dettmer’s Managing Partner Jeff Higgins.
  • To learn more about Gunderson Dettmer's resources in the AI space, click here .

Dassault Aviation: Availability of a complete form of the 2023 Annual Financial Report

Retrieved on: 
Thursday, March 14, 2024
Annual report, Dassault Aviation, Rapport, Aviation, Publication

Dassault Aviation complete version of the 2023 Annual Financial Report (Rapport financier annuel) as of 31 December 2023 is available to the public and has been filed with the French Financial Markets Authority (Autorité des Marchés Financiers), including in ESEF format.

Key Points: 
  • Dassault Aviation complete version of the 2023 Annual Financial Report (Rapport financier annuel) as of 31 December 2023 is available to the public and has been filed with the French Financial Markets Authority (Autorité des Marchés Financiers), including in ESEF format.
  • This financial annual report can be found on the company’s website at www.dassault-aviation.com, in the “Finance / Regulated information / 2024 Regulated information” and “Finance / Publications / 2024 Publications” sections.

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024
JAMA, Research, Health care, Health, Public, Public health, EVP, UCSF School of Medicine, Pediatric Research, Education, UC, Global Health, Emergency medicine, Society, Publication, Emergency medical services, Hospital, Children's National Hospital, Stanford University, National academy, MHA, Pediatrics, BMJ

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

Dr. Xiang Lingyun Joins NUM as Tenured Economics Professor and PhD Advisor

Retrieved on: 
Wednesday, March 13, 2024
NUM, Faculty, Logic, Accounting, International Association, Knowledge, Research, Policy, Doctor of Philosophy, Mentorship, Marquess, Student, IAAP, Publication, FAIA, FCPA, Certified Public Accountant, Economics, National university, Management

Annapolis, Maryland, March 13, 2024 (GLOBE NEWSWIRE) -- Dr. Xiang, known for his extraordinary contributions to the fields of international finance, accounting, and emerging industries, joins NUM as a tenured professor and PhD advisor , bringing with him a wealth of knowledge and a rich tapestry of global experiences.

Key Points: 
  • Annapolis, Maryland, March 13, 2024 (GLOBE NEWSWIRE) -- Dr. Xiang, known for his extraordinary contributions to the fields of international finance, accounting, and emerging industries, joins NUM as a tenured professor and PhD advisor , bringing with him a wealth of knowledge and a rich tapestry of global experiences.
  • Dr. Xiang, known for his extraordinary contributions to the fields of international finance, accounting, and emerging industries, joins NUM as a tenured professor and PhD advisor, bringing with him a wealth of knowledge and a rich tapestry of global experiences.
  • At NUM, Dr. Xiang will be involved in shaping the next generation of economists and finance professionals.
  • The NUM community warmly welcomes Dr. Xiang, looking forward to the inspiration and innovation he brings to the campus.

Phosphorus Appoints Osama AlZoubi as Regional Vice President of Saudi Arabia and Middle East

Retrieved on: 
Wednesday, March 13, 2024
IIT, Organization, NEOM, CPS, Growth, Computer science, Red Sea Project, Digital, Internet of things, RSAC, DEF, Industrial internet of things, Knowledge, Artificial intelligence, Business architecture, University, Software, Engineering, System, IoMT, Kingdom, Digital transformation, Vision 2030, City, Publication, Cisco, OT, Destroy Lonely, Public sector, Patent, Region, UIC, MEA, Cyber-physical system, Computer, ICT, Arms industry

NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) -- Phosphorus Cybersecurity Inc., the leading provider of unified, prevention-based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East.

Key Points: 
  • NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) -- Phosphorus Cybersecurity Inc., the leading provider of unified, prevention-based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East.
  • As one of the world’s fastest growing economic regions, Saudi Arabia and the Middle East are experiencing significant technological progress, particularly in energy, smart manufacturing, and urban development.
  • “Cybersecurity is critically important in fast-developing Saudi Arabia, and across the Middle East region, as more countries invest in advanced technologies, such as smart cities.
  • Prior to joining Phosphorus, AlZoubi held multiple global leadership roles and most recently served as Chief Technology Officer (CTO) for Cisco in the Middle East and Africa.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Development, Gene editing, Growth, Regeneron Pharmaceuticals, Biotechnology, Science and nature, Merck Serono, Patient, Branches of microbiology, Acquisition, Virology, Executive Committee, Max Planck Society, CRISPR Therapeutics, University, Senior, Bayer, Publication, Therapy, Takeda, CRISPR, Amgen, CRSP, Medicine, Pharmaceutical industry

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.

Corti Set to Disrupt the Health Wearable Market with the First Real-time, Continuous Monitor for Cortisol and Melatonin Hormones, the Key Stress and Sleep Hormones

Retrieved on: 
Thursday, April 4, 2024
Wearables, Mobile Technology, Technology, Mental Health, Fitness & Nutrition, Health Technology, Other Health, Health, General Health, Consumer Electronics, Moses Austin, Benchmarking, Hormone, Exercise, Professor, Inflammation, Biomarker, Research, Sleep, Melatonin, University, Doctor of Philosophy, Life, Eye, Diet, Management, Publication, Skin, Cortisol, Ageing, Medical device

The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.

Key Points: 
  • The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.
  • Now, it provides users with unmatched real-time insights into their wellness, establishing a new benchmark for the continuous monitoring of these critical biomarkers.
  • Corti redefines health monitoring by offering continuous, real-time visibility into the body's key stress and sleep hormones, Cortisol and Melatonin, marking a first in the wearable market.
  • Moreover, we are actively working with partnering businesses to discover new applications, enhancing its integration into various health and wellness ecosystems.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

Icertis Named a Customers’ Choice Vendor in 2024 Gartner Peer Insights™ Voice of the Customer for Contract Life Cycle Management Report

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Data Management, Technology, Legal, Software, Artificial Intelligence, Cloud, Microsoft, CLM, Financial Times, Research, Customer, Real-time, Publication, ICI, Human voice, Contract lifecycle management, Gold, Magic Quadrant, Corporation, Magic

Icertis , the global leader in AI-powered contract intelligence, is recognized as a Customers’ Choice vendor in the 2024 Gartner Peer Insights™ Voice of the Customer for Contract Life Cycle Management (CLM) report.

Key Points: 
  • Icertis , the global leader in AI-powered contract intelligence, is recognized as a Customers’ Choice vendor in the 2024 Gartner Peer Insights™ Voice of the Customer for Contract Life Cycle Management (CLM) report.
  • Icertis placed in the top right quadrant based on the company’s customer ratings for overall experience, user experience, and adoption.
  • This distinction follows Icertis’ four-time recognition as a Leader in the Gartner® Magic Quadrant™ for Contract Life Cycle Management .
  • Gartner, Voice of the Customer for Contract Lifecycle Management, Peer Contributors, 22 March 2024
    Gartner®, Magic Quadrant and Peer Insights™ are trademarks of Gartner, Inc. and/or its affiliates.